NEW YORK (GenomeWeb News) – Olink Bioscience and Abnova have agreed to a co-development and co-marketing partnership for protein assays, Olink said today.
Under the agreement, the companies will jointly market hundreds of target-specific assays, and will combine Abnova's collection of antibodies with Olink's Duolink product line. The companies will market the products jointly and each company will handle the sales for its own products, Olink said.
Uppsala, Sweden-based Olink's products are based on in situ proximate ligation assay technology that combines dual recognition of the analyte with a DNA amplification system. It is used to detect single molecular events in fixed cells and tissue and is used in signal transduction and drug mechanism studies.
Abnova, which is based in Taipei, Taiwan, specializes in high-throughput protein expression and antibody production.
Björn Ekström, Olink's CEO, said in a statement that the collaboration "will enable us to provide our customers with convenient and demonstrated assays for defined targets."